Ductal carcinoma in situ (DCIS) accounts for approximately 10% of all newly-diagnosed breast cancers in the UK. The latest national guidelines were published in 2009 and may not reflect current best practice. Using the national surgical trainee research collaborative network, We aimed to explore variation in the current management of DCIS to support the need for updated guidelines.
Introduction
Ductal carcinoma in situ (DCIS) is a pre-invasive breast cancer defined as the malignant clonal proliferation of cells within the basement membrane bound structures of the breast with no evidence of invasion 1 . A condition rarely diagnosed before the introduction of the national breast screening programme as the majority of lesions are impalpable 2 , the age standardised incidence of DCIS has increased seven-fold from 3.3 per 100,000 in 1979 to 21.0 per 100,000 in 2012 3 due to the detection of lesions as microcalcifications on screening mammograms. DCIS now represents 20% of all screen-detected cancers and almost 13% of all new breast cancers in the UK with approximately 6400 new cases diagnosed in 2012 alone 3 .
Although thousands of women are diagnosed with DCIS each year, there is uncertainty regarding its optimal treatment as DCIS is a heterogeneous disease with variable malignant potential 4 . Evidence suggests that if left untreated, up to 35% of lesions may become invasive cancers within 10 years 5 , however not all lesions will progress. Data from the NHS Breast Screening Programme has failed to demonstrate any associated decrease in the incidence of invasive cancers that may have been expected with increased detection and treatment of pre-invasive disease 2 . This has led to concerns regarding both 'overdiagnosis' and 'overtreatment' particularly for low grade lesions. The benefits of diagnosis and treatment of DCIS, however, were recently identified in a study suggesting a decrease in the rate of interval cancers in this group 6 .
In the absence of data to definitively support a conservative approach, surgery aiming to excise the primary lesion and prevent recurrence remains the mainstay of treatment for DCIS. This is important, as although DCIS has low metastatic potential, up to 50% of all recurrences will be invasive disease 7 with the associated risk of metastases and death. Local recurrence rates may be as high as 8% following mastectomy and 21.5% following breast conserving surgery alone 7 . Recent Cochrane reviews have highlighted reductions in local recurrence rates with adjuvant radiotherapy 8 and also with adjuvant tamoxifen 9 in women with ER positive disease managed with breast conservation.
Effective evidence-based guidelines for the management for DCIS are therefore vital if outcomes for patients are to be improved. Both the National Institute of Health and Care Excellence (NICE) 10 and the Association of Breast Surgery (ABS) at the British Association of Surgical Oncology (BASO) 11 Variation in the management of DCIS in the UK 4 have produced guidelines for the management of breast cancer which include recommendations for the management of DCIS (table 1) . However, there are no guidelines specific to the condition and both these publications date from 2009. They therefore do not reflect new evidence regarding the optimal management of DCIS, the development of new surgical techniques such as therapeutic mammoplasty or new prognostic technologies such as Oncotype DX DCIS 12 and may therefore not reflect current best practice.
Using the national surgical trainee research collaborative network, The aim of this study was therefore to explore variations in national practice regarding the management of pure DCIS to support the need for new evidence-based guidelines to standardise practice and improve outcomes for women diagnosed with the condition in the future.
Methods
The Mammary Fold is the UK national breast trainees' association. A national practice questionnaire was developed by members of the Mammary Fold Academic Committee (MFAC) with expert multidisciplinary input from surgeons (Mr Stewart Nicholson), pathologists (Professor Andrew Hanby) and oncologists (Professor David Dodwell) involved in the Sloane Project, a UK wide prospective audit of the management and long term outcomes of screen-detected in situ carcinoma and atypical hyperplasia of the breast [13] [14] [15] [16] . The survey covered all aspects of the management of DCIS including pre-operative assessment and decision-making; intra-operative management and post-operative pathological assessments; decision-making for adjuvant therapy, and follow-up. The survey was piloted by committee members at local units to ensure completeness and determine face and content validity of the survey prior to study initiation.
Trainee research collaboratives 17 consisting of surgical trainees at different units working together to design and deliver of high-quality research 18 and audit 19, 20 are well-established in general surgery and increasingly in sub-specialities such as breast surgery 21 . Trainees working at breast units across the UK were therefore invited to participate in the study via the Mammary Fold and local deaneries. All trainees were medically-qualified doctors in general surgical training.
Participants were asked to complete the survey at their unit's multidisciplinary team meeting (MDT) to
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Study data were collected and managed using REDCap electronic data capture tools hosted at University of Edinburgh 22 . REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3)
automated export procedures for seamless data downloads to common statistical packages; and 4)
procedures for importing data from external sources.
Simple summary statistics were calculated for each survey item to evaluate variations in pre, intra and post-operative assessment and treatment. Appropriate non-parametric statistics were used to explore variables that may influence practice. STATA V13.1 (www.stata.com) was used for all analyses.
Results
A total of 133 records were entered onto the REDCap database. Of these, 15 lacked identifiable unit name and were excluded from the analysis. Of the remaining 118 records, 42 were identified as partially completed duplicates and excluded. A total of 76 units therefore contributed data to the study of which 52 units entered complete data sets.
Unit demographics
Of the 76 participating units, 66 (86.8%) treated both symptomatic patients and those referred from NHS Breast Screening Programme while 9 (11.8%) managed symptomatic patients only. Units with no difference in case volume between screening and symptomatic units (table 2) .
Unit guidelines for the management of DCIS
A total of 47/76 units reported having written guidelines for the management of DCIS. These were most commonly combined with those for invasive disease (n=44) with only three reporting stand-alone guidance for pre-invasive lesions (table 2) .
Pre-operative imaging
Variation in the management of DCIS in the UK 6 Pre-operative assessment varied widely between units. Ultrasound was used routinely for planning surgery in 33/76 units, but five units did not routinely scan patients pre-operatively and a further 16 did so only in selected cases, most commonly when the lesion was palpable (n=8).
In line with NICE guidance 10 , MRI was not routinely used in pre-operative planning for DCIS and over a third of units (n=27) reported that they never used this imaging modality in patients with pre-invasive disease. A number of units (n=27) reported using MRI in specific circumstances including when there is uncertainty about the extent of the DCIS (n=5); mammographically occult lesions (n=5); size discrepancies between imaging modalities (n=4) or if invasive foci were anticipated in high-grade (n=2) or large lesions (n=3).
The axilla was routinely imaged by USS in almost half of responding units (n=33) with only 3 units reporting that the axilla was never imaged pre-operatively in DCIS patients. A further 15 units imaged the axilla selectively. Indications for axillary imaging in these units included the presence of a palpable mass (n=6), other features that may predict invasion (n=18), or if a mastectomy was planned (n=3).
Pre-operative pathological diagnosis
Core biopsy was the first line for establishing a diagnosis of DCIS in many of the units surveyed (n=17). The use and availability of vacuum-assisted biopsy (VAB) was much more restricted with only 8 units reporting that it was first line for the diagnosis of microcalcifications. VAB was not available in seven units and available but not used in a further 11. Eight units used VAB in selected cases including small lesions and lesions in which the diagnosis was difficult.
Indications for mastectomy
To reduce the risk of recurrence, the ABS at BASO guidelines recommend patients with 'extensive' (greater than 40mm) or multicentric disease should usually undergo a mastectomy 11 . Multifocality was considered an indication for mastectomy by many units (n=29), but size criteria were less consistently applied. Eleven units used 40mm as an indication for mastectomy but seven units reported offering breast conservation for up to 50mm of DCIS. A further 13 units reported that they considered the size of the lesion in relation to the size of the breast rather than applying an absolute Variation in the management of DCIS in the UK 7 size criterion when considering whether breast conservation was feasible. A quarter of units (n=19) reported having no specific indications for mastectomy and assessed patients on a case by case basis (table 2) .
Breast reconstruction was offered to women requiring mastectomy by the majority of units (57/76) with 34/76 units offering women the possibility of nipple sparing procedures if the lesion was away from the nipple-areolar complex (n=9) or a subareolar biopsy was clear of disease (n=6). Therapeutic mammoplasty was also widely offered (n=49).
Sentinel node biopsy
Current guidelines recommend performing a sentinel lymph node biopsy (SLNB) in patients at high risk of invasive disease or those undergoing mastectomy 11 . Although the majority of units (n=51/76) reported undertaking SLNB when mastectomy was performed, there was a lack of consistency regarding other indications. Those reported were variable but included performing SLNB for massforming/palpable (n=33); high-grade (n=8) or multifocal (n=6) lesions (table 2) .
Intra-operative assessment of excision specimens
The ABS at BASO guidelines 11 recommend that intra-operative specimen radiography should be performed in all cases of DCIS treated with breast conserving surgery (BCS). Only 27 units, however, routinely imaged their excision specimens intra-operatively. Twenty-three units used specimen radiography for wire-guided excisions only. One unit reported that intraoperative imaging was not available and a further unit reported that it was never performed. Portable imaging devices and departmental imaging were used with equal frequency (table 2) .
For those patients undergoing SLNB, One
Step Nucleic Acid Amplification (OSNA) was used routinely in DCIS in seven units, but was not available in the majority of the remainder (n=42).
Pathological assessment
NICE guidance recommends a minimum of a 2mm excision margin in patients with DCIS to reduce the risk of local recurrence 10 . Twenty-eight units followed this guidance, but there was a lack of consensus regarding what was considered an acceptable margin. Following the recent ABS Variation in the management of DCIS in the UK 8 consensus process, 17 units reported using a 1mm margin and a further six units used 'no tumour on ink' consistent with the SSO (Society of Surgical Oncology)/ASTRO (American Society for Radiation Oncology) guidelines for invasive disease 23 . One unit reported that 5mm was the minimum acceptable margin and a further unit reported that margin width depended on the grade of disease with a 10mm margin required for high-grade DCIS.
Routine receptor status testing in DCIS was very variably applied. Oestrogen receptor status was routinely assessed by 22 units; progesterone receptor status by 17 units and HER-2 status by only eight. Where receptor status was determined, this was predominantly on the core biopsy specimen (n=15) with a minority using tissue from the excision specimen itself (n=3). Seven units assessed receptor status on both the biopsy and excision specimens.
In terms of risk stratification, the Van Nuys Prognostic Index was only used routinely by 12 units. A further five units used it in certain circumstances such as when considering radiotherapy or for high grade disease. The newly developed Oncotype DX DCIS recurrence score was only used routinely by one unit and was not available in the remainder.
Adjuvant therapy
Although NICE guidelines recommend against offering patients with DCIS endocrine therapy 10 , six units routinely did so and a further 12 offered treatment to patients considered to be a high risk of recurrence such as young patients with high-grade disease.
The offer of radiotherapy (RT), including a discussion of the risks and benefits of treatment, is currently recommended for all women having BCS for DCIS 10 . Although ten units routinely offer RT on this basis, other units offer RT to selected patients only. A lack of consensus was demonstrated regarding the indications for treatment with tumour grade (n=39), size (n=27), patient age (n=23), presence of comedo necrosis (n=21) and margin width most frequently influencing recommendations for RT. The Van Nuys Prognostic Index was used infrequently in decision making (n=10) and when it was calculated, there was a lack of consistency with regard to the scores that would determine whether RT would be beneficial (table 2) .
Follow-up
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There was similar variability in the way patients with DCIS were followed up across the UK. 
Discussion
This survey demonstrates marked variation in the management of pure DCIS across breast units in the UK. There is a lack of consistency with regard to pre-operative planning; intra-operative practice This study has demonstrated significant variability in the current management of DCIS across the UK. This is an important finding, but some aspects of the work require further consideration. Firstly, the results are based on survey data and it may be that actual practice in the individual units differs from the responses provided. There may also be response bias with participating units differing significantly from those that were not involved. The broad variability and general lack of adherence to current guidance observed, however, suggests that this is unlikely. Furthermore, the 
Surgical management of DCIS
Intra-operative specimen radiography should be carried out for all cases of DCIS treated by BCS ABS at BASO For all patients treated with BCS for DCIS a minimum of 2 mm radial margin of excision is recommended with pathological examination to NHSBSP reporting standards. Re-excision should be considered if the margin is less than 2 mm, after discussion of the risks and benefits with the patient.
NICE CG80
All patients should have their tumours removed with no evidence of disease at the microscopic radial margins and fulfilling the requirements of local guidelines If, after MDT meeting discussion, the margin of excision is deemed to be inadequate then further surgery to obtain clear margins should be recommended ABS at BASO Axillary staging surgery is not routinely recommended for patients having treatment for DCIS alone. It may be considered in patients considered to be at high risk of occult invasive disease. The decision to carry out an axillary staging procedure should be discussed at the pre-operative MDT meeting and recorded in the patient's case notes.
ABS at BASO
Do not perform SLNB routinely in patients with a preoperative diagnosis of DCIS who are having BCS, unless they are considered to be at a high risk of invasive disease (high risk of invasive disease includes those with a palpable mass or extensive microcalcifications)
NICE CG80
Offer SLNB to all patients who are having a mastectomy for DCIS NICE CG80
Post-operative adjuvant therapy in DCIS
Do not offer adjuvant tamoxifen after breast conserving surgery to patients with DCIS NICE CG80
Offer adjuvant radiotherapy to patients with DCIS following adequate BCS and discuss with them the potential benefits and risks NICE CG80
Follow-up in DCIS
Offer annual mammography to all patients with early breast cancer, including DCIS, 
